No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
www.hengrui.comNo one on the platform currently holds 600276.SS.
No tracked institution reports a position in 600276.SS as of their last filing.
No one on the platform has traded 600276.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 33.4% | 25.2% | 27.2% | — | — | — |
| Rev. Growth % | 12.3% | 2.5% | ||||
| Profit Margin % | 24.5% | 20.4% | 21.8% | |||
| Free Cash Flow Margin % | 26.5% | 15.9% | 14.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $33.7B | +2.6% | $1.38 | $1.30–$1.44 | — | 11 |
| 2027 | $38.3B | +13.7% | $1.54 | $1.38–$1.72 | — | 10 |
| 2028 | $44.0B | +14.7% | $1.82 | $1.53–$2.52 | — | 14 |
| 2029 | $59.6B | +35.6% | $2.88 | $2.83–$3.09 | — | 7 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-19 | $0.41 | $0.33 | -19.1% |
| 2026-04-22 | $0.33 | $0.34 | +2.9% |
| 2026-03-25 | $0.34 | $0.31 | -10.3% |
| 2025-10-23 | $0.30 | $0.20 | -32.4% |
| 2025-08-20 | $0.31 | $0.40 | +27.0% |
| 2025-05-30 | $0.29 | $0.29 | -0.9% |
| 2024-12-31 | $0.21 | $0.27 | +28.9% |
| 2024-10-24 | $0.23 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600276.SSJiangsu Hengrui Medicine Co., Ltd. | $43.13 | -0.05% | $275.1B | — |
| 000705.SZZhejiang Zhenyuan Share Co., Ltd. | $6.88 | -3.64% | $2.3B | — |
| 000908.SZHunan Jingfeng Pharmaceutical Co.,Ltd. | $6.08 | -1.78% | $10.7B | — |
| 002019.SZYifan Pharmaceutical Co., Ltd. | $9.24 | -0.75% | $11.2B | — |
| 002422.SZSichuan Kelun Pharmaceutical Co., Ltd. Class A |
| $0.19 |
| -17.4% |
| $40.65 |
| -1.76% |
| $64.7B |
| — |
| 300357.SZZhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | $18.92 | -0.68% | $9.9B | — |
| 300760.SZShenzhen Mindray Bio-Medical Electronics Co., Ltd. | $160.30 | +0.12% | $194.4B | — |
Source: Financial Modeling Prep · peers by sector/industry